EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders

Carolyn J Straub iD, Lisa E Rusali, Kyle M Kremiller, Andrew P Riley iD

Journal of Medicinal Chemistry · 12.01.2023 · 66 (1) · 107-121

DOI: 10.1021/acs.jmedchem.2c01562 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 28.11.2022. Verfasst von Carolyn J Straub und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States. Hauptthemen laut MEDLINE: Ibogaine, Receptors, Nicotinic, Substance-Related Disorders. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 165 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIGMS NIH HHS, NCCIH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For decades, ibogaine─the main psychoactive alkaloid found in Tabernanthe iboga─has been investigated as a possible treatment for substance use disorders (SUDs) due to its purported ability to interrupt the addictive properties of multiple drugs of abuse. Of the numerous pharmacological actions of ibogaine and its derivatives, the inhibition of α3β4 nicotinic acetylcholine receptors (nAChRs), represents a probable mechanism of action for their apparent anti-addictive activity. In this Perspective, we examine several classes of compounds that have been discovered and developed to target α3β4 nAChRs. Specifically, by focusing on compounds that have proven efficacious in pre-clinical models of drug abuse and have been evaluated clinically, we highlight the promising potential of the α3β4 nAChRs as viable targets to treat a wide array of SUDs. Additionally, we discuss the challenges faced by the existing classes of α3β4 nAChR ligands that must be overcome to develop them into therapeutic treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IbogaineReceptors, NicotinicSubstance-Related DisordersHumansDose-Response Relationship, Drug

Substanzen

IbogaineReceptors, Nicotinic

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States.

ORCID-Profile: Carolyn J Straub, Andrew P Riley

Förderung

  • NCATS NIH HHS
  • NIGMS NIH HHS
  • NCCIH NIH HHS
  • National Institutes of Health

Zitieren

APA

Straub, C. J., Rusali, L. E., Kremiller, K. M., & Riley, A. P. (2023). What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders. Journal of Medicinal Chemistry, 66(1), 107-121. https://doi.org/10.1021/acs.jmedchem.2c01562

Vancouver

Straub CJ, Rusali LE, Kremiller KM, Riley AP. What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders. Journal of Medicinal Chemistry. 2023;66(1):107-121. doi:10.1021/acs.jmedchem.2c01562

BibTeX
@article{Straub2023,
  author = {Straub, Carolyn J and Rusali, Lisa E and Kremiller, Kyle M and Riley, Andrew P},
  title = {What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {1},
  pages = {107--121},
  doi = {10.1021/acs.jmedchem.2c01562}
}
Kostenlos starten →